Research progress of programmed death 1 immune-targeted therapy for B-cell lymphoma / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
;
(12): 45-48,56, 2016.
Artículo
en Chino
| WPRIM
| ID: wpr-603329
ABSTRACT
The inhibitors of programmed death 1 (PD-1)/PD-1 ligand (PD-L1) become a highlight in tumor immunotherapy and provide a new direction for immune-targeted therapy for cancer. More and more studies have confirmed that PD-1/PD-L1 inhibitors could improve effects and be well-tolerated. Early clinical trials of PD-1 inhibitors have shown significant clinical efficacy in various solid tumours. The unique role of the PD-1 pathway in lymphoma has been found gradually. This article summarized the advancement of PD-1 in B-cell lymphoma therapy.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Journal of Leukemia & Lymphoma
Año:
2016
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS